v3.26.1
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Operating expenses:    
General and administrative expenses $ 13,697,817 $ 11,381,978
Research and development 16,258,598 11,292,702
Total operating expenses 29,956,415 22,674,680
Loss from operations (29,956,415) (22,674,680)
Other income:    
Interest income 555,526 1,017,354
Total other income 555,526 1,017,354
Loss before provision for income taxes (29,400,889) (21,657,326)
Provision for income taxes 37,724 41,037
Net loss (29,438,613) (21,698,363)
Net loss attributable to non-controlling interests 84,987
Net loss attributable to Immix Biopharma, Inc. common stockholders (29,438,613) (21,613,376)
Other comprehensive income (loss):    
Foreign currency translation 61,216 (135,722)
Total other comprehensive income (loss) 61,216 (135,722)
Comprehensive loss $ (29,377,397) $ (21,749,098)
Loss per common share - basic $ (0.89) $ (0.76)
Loss per common share - diluted $ (0.89) $ (0.76)
Weighted average shares outstanding - basic 32,965,706 28,285,637
Weighted average shares outstanding - diluted 32,965,706 28,285,637